INVITROCUE LIMITED (ASX.IVQ)

Shareholders in this company should consider crystallising a capital loss in 2023/24 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

delisted from the commencement of trading on Monday, 1 March 2021, pursuant to Listing rule 17.12.

we understand this company failed and ASX removed the company from listing because it failed to lodge a document with ASX for a period of one year after the deadline for lodgement of that document

The Company intends to establish an opt-out unmarketable parcel sale facility for shareholders who hold less than $500 worth of fully paid ordinary IVQ shares.

The company lodges its Appendix 4C - quarterly.

The company lodges its Appendix 4C - quarterly.

Through its 70% owned subsidiary company Invivocue Pte Ltd, IVQ has completed development of ACE-2 Humanised Immune Mice platform. Currently under validation study with Duke NUS in Singapore. Expected scientific publication with validation data in coming months. In research partnership with Pangaea Oncology SA, IVQ secured first commercial pilot contract to supply ACE-2 HiMice to Pharma Mar SA.

The company lodges its Appendix 4C - quarterly.

The company releases its 4C Commentaries and Management Updates.

The company lodges its Appendix 4C - quarterly.

Invitrocue has successfully registered CE Mark for its Onco-PDO Cancer Test. The CE Mark allows the test to be sold in the European Economic Region.

Memorandum of Understanding entered into for the establishment of Invitrocue Brazil, a joint venture with Brazilian partners. Invitrocue Brazil intends to offer Invitrocue's proprietary personalised cancer test to private-paying patients in Brazil and the rest of Latin America. Test work will be carried out in lab in Brazil that will be fully funded by local partners.

The company releases its 4C Commentaries and Management Updates. The highlights are as follows: 4C Commentaries - Collection for the quarter of SGD$338,000 is higher compared to previous quarter of SGD$181,000; and Combined Onco-PDO and HiMice business continues to attract new funding. Management Updates - US$750,000 of convertible notes placed in Dec 2019; Additional funding of up to US$10 million conditionally agreed; Integrating Onco-PDOand HiMice in new service platform that has clinical and pharmacology applications; German validation study started final Cohort 2; Secured major client for Pharmacology services.

The company lodges its Appendix 4C - quarterly.

The company issues a response to ASX query.

The company issues a cleansing prospectus for the offer of 5 shares at an issue price of $0.20 per share to raise $1.

The company releases a notification of a proposed issue of securities.

The company has entered into a subscription agreement with ChinaLink Limited of up to US$10 million in 2 tranches and has formed a joint venture with the investor. The first 25 cases expected to be completed in Q1 2020. The validation study is expected to last 1 to 2 years, and the Investment spanning over 2 or more financial years. The investor will subscribe for the company shares at the lower of A$0.045 per share or the VWAP of the Shares over 5 trading days prior to completion of each tranche of the subscription for shares.

The company releases the results of its meeting.

The company lodges its Appendix 4C - quarterly.

The company's AGM will be held at the office of Invitrocue Pte Ltd, 11 Biopolis Way, Helios #12-07/08, Singapore 138667 on 27 November 2019 commencing at 4.00pm (Singapore time).

The company has today received notices of resignations from Professor Hanry Yu, Mr Kit Wei Lui and Ms Ee Ting Ng as directors of the company. As the directors whom are the subject of the general meeting resolutions have resigned, there is no resolution to move at the meeting. Accordingly, in accordance with clause 9.7 of the company's constitution, the board has determined to cancel the meeting.

The company releases the results of its meeting.

The company releases an Appendix 4G.

The company releases its Corporate Governance Statement.

The company lodges its Appendix 4E and Annual Report.

The company establishes Hong Kong Laboratory. This will provide greater access to oncologists and patients in Greater China region of mainland China, Hong Kong and Macau. This will be used for R&D and commercial purposes. Lab is currently being equipped and will be completed and operational by November 2019. Hired key staff for the lab including a General Manager.

The company provides the following update: Commenced clinical validation with Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center Munich, Germany; Study uses IVQ's personalised oncology approach to evaluate the effect of cancer drugs on the patients' own unique tumour cells in the lab; Results from cohort 1 of the study are expected within the next quarter and initial results are positive.

The company releases the response by Non-Executive Directors Prof Hanry Yu and Mr Kit Wei Lui to the Notice of Meeting (released on 17 September 2019) in accordance with the right of directors to put their case to members pursuant to section 203D(4) of the Corporations Act.

Notice is hereby given that a General Meeting of Shareholders of the Company be called at the request of Dr Steven Fang, Dr Andreas Lindner, Dr Gary Pace and Mr Geoffrey Thomas severally as directors of Invitrocue Limited. The meeting will be held on 18 October 2019 at 2.00pm Perth time at The Executive Centre, Room 25A, Level 25, 108 St Georges Terrace, Perth WA 6000, Australia.

In relation to the notice of meeting released by three directors which details the removal of Dr. Boon Sing Fang as director, Dr. Boon Sing Fang issues a response in accordance with the right of directors to put their case to members.

The company makes a correction to the incorrect registered address indicated in the proxy form released this morning.

The company provides an updated proxy form for the notice of meeting.

On 11 September 2019, the company received a further Notice of Intention pursuant to Section 203D(2) of the Corporations Act from directors Prof Hanry Yu, Ms Ee Ting Ng and Mr Kit Wei Lui to move a resolution at a general meeting for the removal of Geoffrey David Edwin Thomas as director of the company.

The company releases a notice of general meeting. The meeting will be held at the offices of Macpherson Kelley, Level 21, 20 Bond Street, Sydney 2000 on 11 October 2019 at 11:00 am, Sydney time.

In relation to the S203D notices, the directors are having ongoing dialogues with the parties involved.

The company issues a cleansing statement. It has issued and allotted 16,096,667 shares and 3,219,334 options to investors via private placements.

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

The securities of Invitrocue Limited will be suspended from quotation immediately under Listing Rule 17.3.

name changed from Bunuru Corporation Limited